Tags

Type your tag names separated by a space and hit enter

Focus on anastrozole and breast cancer.
Curr Med Res Opin. 2003; 19(8):683-8.CM

Abstract

This commentary article provides an overview of recent clinical research trials involving anastrozole and its evolving role in the management of breast cancer. Anti-aromatase agents inhibit the cytochrome P-450 component of the aromatase enzyme complex responsible for the final step of estrogen biosynthesis in peripheral tissues which are the main source of estrogen in postmenopausal women. Anastrozole is a third-generation non-steroidal aromatase inhibitor. It has been shown to be superior to megestrol acetate, in terms of survival and adverse effects, as a second-line therapy in postmenopausal women with estrogen receptor (ER)- and/or progesterone receptor (PgR)-positive advanced breast cancer. Phase III clinical trials have also demonstrated that anastrozole significantly prolongs the time to tumour progression compared with tamoxifen as a first-line therapy for ER- and/or PgR-positive advanced breast cancer in postmenopausal women. Furthermore, the preliminary results of the Arimidex, Tamoxifen, Alone and in Combination (ATAC) study have shown that adjuvant anastrozole is superior to tamoxifen in terms of disease-free survival (DFS), non-musculoskeletal adverse effects and prevention of contralateral breast cancer in postmenopausal women with early, ER-positive breast cancer. Although longer follow-up is required to assess the long-term effects of anastrozole on bone mineral density, cognitive function and overall survival, the drug has been recently approved for adjuvant use in postmenopausal women with early, ER-positive breast cancer who are unable to tolerate tamoxifen or at an increased risk of developing thromboembolism or endometrial cancer. The potential role of anastrozole in the neoadjuvant setting, the management of DCIS, premenopausal breast cancer and breast cancer prevention is currently being investigated.

Authors+Show Affiliations

St George's Hospital and Medical School, London, UK. kefahmokbel@hotmail.com

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

14687437

Citation

Mokbel, K. "Focus On Anastrozole and Breast Cancer." Current Medical Research and Opinion, vol. 19, no. 8, 2003, pp. 683-8.
Mokbel K. Focus on anastrozole and breast cancer. Curr Med Res Opin. 2003;19(8):683-8.
Mokbel, K. (2003). Focus on anastrozole and breast cancer. Current Medical Research and Opinion, 19(8), 683-8.
Mokbel K. Focus On Anastrozole and Breast Cancer. Curr Med Res Opin. 2003;19(8):683-8. PubMed PMID: 14687437.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Focus on anastrozole and breast cancer. A1 - Mokbel,K, PY - 2003/12/23/pubmed PY - 2004/8/31/medline PY - 2003/12/23/entrez SP - 683 EP - 8 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 19 IS - 8 N2 - This commentary article provides an overview of recent clinical research trials involving anastrozole and its evolving role in the management of breast cancer. Anti-aromatase agents inhibit the cytochrome P-450 component of the aromatase enzyme complex responsible for the final step of estrogen biosynthesis in peripheral tissues which are the main source of estrogen in postmenopausal women. Anastrozole is a third-generation non-steroidal aromatase inhibitor. It has been shown to be superior to megestrol acetate, in terms of survival and adverse effects, as a second-line therapy in postmenopausal women with estrogen receptor (ER)- and/or progesterone receptor (PgR)-positive advanced breast cancer. Phase III clinical trials have also demonstrated that anastrozole significantly prolongs the time to tumour progression compared with tamoxifen as a first-line therapy for ER- and/or PgR-positive advanced breast cancer in postmenopausal women. Furthermore, the preliminary results of the Arimidex, Tamoxifen, Alone and in Combination (ATAC) study have shown that adjuvant anastrozole is superior to tamoxifen in terms of disease-free survival (DFS), non-musculoskeletal adverse effects and prevention of contralateral breast cancer in postmenopausal women with early, ER-positive breast cancer. Although longer follow-up is required to assess the long-term effects of anastrozole on bone mineral density, cognitive function and overall survival, the drug has been recently approved for adjuvant use in postmenopausal women with early, ER-positive breast cancer who are unable to tolerate tamoxifen or at an increased risk of developing thromboembolism or endometrial cancer. The potential role of anastrozole in the neoadjuvant setting, the management of DCIS, premenopausal breast cancer and breast cancer prevention is currently being investigated. SN - 0300-7995 UR - https://www.unboundmedicine.com/medline/citation/14687437/Focus_on_anastrozole_and_breast_cancer_ L2 - https://www.tandfonline.com/doi/full/10.1185/030079903125002397 DB - PRIME DP - Unbound Medicine ER -